BTK inhibitors

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Merck Sharp & Dohme Corp. patent solves the following problem:

B lymphocyte activation is key to the generation of adaptive immune responses. Derailed B lymphocyte activation is a sign of many autoimmune diseases and in the modulation of the immune response and therapeutic interest. Recently the success of B cell therapy in autoimmune disease is established. Treatment of rheumatoid arthritis (RA) patients with Rituximab (anti-CD20 therapy) is an accepted clinical therapy today. More recent clinical trial studies showed that treatment with Rituximab also ameliorates symptoms of the disease in relapsing remitting multiple sclerosis (RRMS) and systemic lupus erythematosus (murder) patients. This success supports the potential for future therapies for autoimmune diseases targeted B cell immunity.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp.’s patent US 9446130 B2 deals with BTK inhibitors.
The present invention provides Bruton's tyrosine kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salt thereof. Formula I or a pharmaceutically acceptable salt thereof or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds for the treatment of Btk mediated disorder.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Merck Sharp & Dohme Corp. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus pharmacologically interfering SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp.’s patent US 9416111 B2 deals with Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors.
invention provides certain substituted diazine and triazine compounds of Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, P3, R4, rcy, CY, and t as described here. invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated spleen tyrosine kinase (SYK) kinase.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Aerodynamic device for the rear of a trailer

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Trailstar International, Inc. patent solves the following problem:

The present invention relates generally to the field of aerodynamic devices to reduce drag. Particularly, the present invention relates to a flying device adapted to extend from the back of a trailer or semi-trailer container. In particular, the present invention relates to an air intake scoop and an inflatable member extending outwardly from a trailer.

Our analysis of this patent is as follows:

Trailstar International, Inc.’s patent US 9371097 B1 deals with Aerodynamic device for the rear of a trailer.
A flying device for a trailer includes an inflatable member with a back wall of a trailer adapted to inflate its rearwardly to reduce drag as the trailer pulled forwardly. The flying device further includes an air intake scoop mounted under the rear wall of the trailer in fluid communication with inflatable member filling the inflatable member in the air as the trailer moves forward.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Chemoenzymatic synthesis of heparin and heparan sulfate analogs

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The The Regents Of The University Of California patent solves the following problem:

Our analysis of this patent is as follows:

The Regents Of The University Of California’s patent US 9290530 B2 deals with Chemoenzymatic synthesis of heparin and heparan sulfate analogs.
The present invention provides a one-pot multi-enzyme method for preparing the UDP-sugars from simple sugar starting materials. invention also provides a one-pot multi-enzyme process for the preparation of oligosaccharides from simple sugar starting materials.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Dosage and formulation

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Almirall, S.A. patent solves the following problem:

Aclidinium bromide is 3 (R) – (2-hydroxy-2,2-dithien-2-ylacetoxy) -1- (3-phenoxypropyl) -1-azoniabicyclo [2.2.2] octane bromide, described in, for example WO 0104118. Although this compound is known as a long-acting anticholinergic useful in the treatment of respiratory diseases, the optimal dose was not disclosed.

Our analysis of this patent is as follows:

Almirall, S.A.’s patent US 9254262 B2 deals with Dosage and formulation.
The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder in a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Compositions having reduced frictional coefficient, method of manufacture thereof and articles comprising the same

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Sabic Global Technologies B.V. patent solves the following problem:

It disclosure relates to compositions that reduce frictional coefficients, means to do so, and articles comprising the same.

Our analysis of this patent is as follows:

Sabic Global Technologies B.V.’s patent US 9169371 B2 deals with Compositions having reduced frictional coefficient, method of manufacture thereof and articles comprising the same.
Expressed here is a composition consisting of an organic polymer and about 2 to 10 weight percent of an ionic liquid. The ionic liquid can be a halogenated or non-halogenated ionic liquid. Also disclosed in articles made from the composition.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The N.V. Nutricia patent solves the following problem:

During the common process of nutrition in food proteins presented to the immune system through the gastro-intestinal tract without an immune response to ingested nutrients. This unresponsiveness is called oral immune tolerance or oral tolerance. The induction of oral immune tolerance is especially relevant for children, after being exposed for the first time to eat protein and adapt to it. If the children's oral immune tolerance is established, food allergies occur. The people who suffer from food allergies requires a specific food protein food to avoid.

Our analysis of this patent is as follows:

N.V. Nutricia’s patent US 9060996 B2 deals with Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins.
Composition and the manner in which the child nutrition partially hydrolysed protein and non-digestible oligosaccharides for use in the induction of oral tolerance against the native of dietary protein.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Autonomous computer session capacity estimation

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Citrix Systems, Inc. patent solves the following problem:

Providing end users with a virtualization environment may present load balancing challenges. The other load balancing system to fail to respond to all these challenges. Systems designed to deliver a virtualized environment on an end user must load balance user load among different physical machines include systems. There are many challenges associated with trying to forecast and plan for the amount of resources needed for a particular user. At any point in time, a user who needs more or less resources. When a system is overloaded or not properly load balance, the system may not be able to provide a user with the necessary resources in a reasonable amount of time thereby reducing the user- experience of an end user.

Our analysis of this patent is as follows:

Citrix Systems, Inc.’s patent US 9052953 B2 deals with Autonomous computer session capacity estimation.
Systems and methods disclosed estimates and update the capacity associated with the resources in a virtualized computing environment. A capacity value estimation can be stored in computer memory. The rate of capacity estimation to estimate how many simultaneous sessions in a virtualized computing resources around work desirably staff capacity. The system can monitor one or more resource resource consumption metrics on an ongoing basis. The capacity price projection will be updated based on, inter alia, the monitoring. The capacity value estimation can be used when a request received to create a new session of resources.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Compounds

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Glaxo Group Limited patent solves the following problem:

Syk is a non-receptor tyrosine kinase involved in coupling activated immunoreceptors signal consuming events that mediate diverse cellular responses, including proliferation, distinction, and phagocytosis. Syk is widely expressed in hematopoietic cells. Syk inhibitor with potential anti-inflammatory and immunomodulating activities. They inhibit SYK-mediated IgG Fc epsilon and gamma receptor and BCR receptor signaling, resulting in inhibition of activation of mast cells, macrophages, and B-cells and relevant inflammatory responses and tissue damage. Mast cells play a major role in type I hypersensitivity reactions associated with urticaria, bronchial asthma, anaphylaxis and other allergic conditions. Therefore, SYK inhibitor has attracted interest from a number of therapeutic areas, including the treatment of rheumatoid arthritis, B-cell lymphoma, asthma, rhinitis and cutaneous disorders such as acute and chronic urticaria, mastocytosis, cutaneous lupus , atopic dermatitis, autoimmune bullous conditions including Pemphigus and pemphigoid and other mast cell mediated skin disease.

Our analysis of this patent is as follows:

Glaxo Group Limited’s patent US 8993560 B2 deals with Compounds.
A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potential use in the treatment of diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for example inflammatory diseases and / or allergic conditions, in cancer therapy, especially heme malignancies, and autoimmune conditions.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Merck Sharp & Dohme Corp. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus pharmacologically interfering SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp.’s patent US 8987456 B2 deals with 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors.
invention provides certain 3-pyridyl formamide-containing compounds of Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein A and B as described here. invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated spleen tyrosine kinase (SYK) kinase.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.